论文信息 - A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma - 字舞流文

A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma

K. Rau | Chiun Hsu | W. Yeo | M. Jeffers | Joong-Won Park | C. Yen | R. Poon | H. Lim | J. Heo | P. Rajagopalan | W. Tak | W. Hsieh | Ho Yeong Lim | H. Choi | H. Krissel | C. Kappeler | Cheng-Yao Lin | M. Tay | J. Yoon | Jung‐Hwan Yoon